Association between p53 Arg72Pro polymorphism and thyroid cancer risk: A meta-analysis

Tumor Biology

Volumn 35, Issue 1, 2014, Pages 561-565

  Wu, Bo ^a   Guo, Dan ^a   Guo, Ying ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Meta analysis; P53; Polymorphism; Thyroid cancer

Indexed keywords

ARGININE; PROLINE; PROTEIN P53;

ARTICLE; ASIAN; CANCER RISK; CAUCASIAN; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; PRIORITY JOURNAL; RISK FACTOR; THYROID CANCER; TUMOR SUPPRESSOR GENE;

ALLELES; CASE-CONTROL STUDIES; CODON; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PUBLICATION BIAS; RISK; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84894454728     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1078-3     Document Type: Article

References (23)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Goyal N, Setabutr D, Abdulghani J, Goldenberg D. Molecular and genetic markers of follicular-cell thyroid cancer: etiology and diagnostic and therapeutic opportunities. Adv Exp Med Biol. 2013;779:309-26.
3. McLeod DS, Sawka AM, Cooper DS. Controversies in primary treatment of low-risk papillary thyroid cancer. Lancet. 2013;381:1046-57.
4. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13:184-99.
5. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013;381:1058-69.
6. Alt FW, Zhang Y, Meng FL, Guo C, Schwer B. Mechanisms of programmed DNA lesions and genomic instability in the immune system. Cell. 2013;152:417-29.
7. Papamichos-Chronakis M, Peterson CL. Chromatin and the genome integrity network. Nat Rev Genet. 2013;14:62-75.
8. Hunt CR, Ramnarain D, Horikoshi N, Iyengar P, Pandita RK, Shay JW, et al. Histone modifications and DNA double-strand break repair after exposure to ionizing radiations. Radiat Res. 2013;179:383-92.
9. Wade M, Li YC, Wahl GM. Mdm2, mdmx and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013;13:83-96.
10. Bellini MF, Cadamuro AC, Succi M, Proenca MA, Silva AE. Alterations of the tp53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol. 2012;2012:891961.
11. Habbous S, Pang V, Eng L, Xu W, Kurtz G, Liu FF, et al. P53 arg72pro polymorphism, hpv status and initiation, progression, and development of cervical cancer: a systematic review and metaanalysis. Clin Cancer Res. 2012;18:6407-15.
12. Boltze C, Roessner A, Landt O, Szibor R, Peters B, Schneider-Stock R. Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma. Int J Oncol. 2002;21:1151-4.
13. Granja F,Morari J,Morari EC, Correa LA, Assumpcao LV,Ward LS. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer Lett. 2004;210:151-7.
14. Bufalo NE, Leite JL, Guilhen AC, Morari EC, Granja F, Assumpcao LV, et al. Smoking and susceptibility to thyroid cancer: an inverse association with cyp1a1 allelic variants. Endocrinol Relat Cancer. 2006;13:1185-93.
15. Rogounovitch TI, Saenko VA, Ashizawa K, Sedliarou IA, Namba H, Abrosimov AY, et al. Tp53 codon 72 polymorphism in radiationassociated human papillary thyroid cancer. Oncol Rep. 2006;15:949-56.
16. Siraj AK, Al-Rasheed M, Ibrahim M, Siddiqui K, Al-Dayel F, Al- Sanea O, et al. Rad52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in middle eastern population. J Endocrinol Investig. 2008;31:893-9.
17. Akulevich NM, Saenko VA, Rogounovitch TI, Drozd VM, Lushnikov EF, Ivanov VK, et al. Polymorphisms of DNA damage response genes in radiation-related and sporadic papillary thyroid carcinoma. Endocrinol Relat Cancer. 2009;16:491-503.
18. Reis AA, Silva DM, Curado MP, da Cruz AD. Involvement of cyp1a1, gst, 72tp53 polymorphisms in the pathogenesis of thyroid nodules. Genet Mol Res. 2010;9:2222-9.
19. Barbieri RB, Bufalo NE, Cunha LL, Assumpção LV, Maciel RM, Cerutti JM, et al. Genes of detoxification are important modulators of hereditary medullary thyroid carcinoma risk. Clin Endocrinol (Oxf). 2013;79(2):288-93. doi:10.1111/cen.12136.
20. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101-29.
21. DerSimonian R, LairdN.Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
22. Mantel N, HaenszelW. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
23. Weng Y, Lu L, Yuan G, Guo J, Zhang Z, Xie X, et al. P53 codon 72 polymorphism and hematological cancer risk: an update metaanalysis. PLoS One. 2012;7:e45820.